CETP and Alzheimer disease: Despite the failed trials listed above, one CETP inhibitor, obicetrapib, is advancing through clinical trials mainly for cardiovascular outcomes (NCT05972278, NCT05142722, NCT05425745, NCT4753606, NCT04770389, NCCT05421078, NCT06005597, NCCT05202509, NCT05266586), with one proof-of-concept open label phase 2a trial in early AD patients to evaluate plasma and CSF lipoprotein changes (NCT05161715).